ADVOCATE
2021
Avacopan for ANCA-Associated Vasculitis
In 331 patients with ANCA-associated vasculitis, the oral C5a-receptor antagonist avacopan improved sustained remission at week 52 compared with a tapering prednisone regimen.
Result
- Absolute difference
- 10.8 points
- NNT
- 10
Absolute difference and NNT are derived from the event rates.
Also reported: Week 26 non-inferior (72.3% vs 70.1%);
- Subtopic
- ANCA vasculitis
- Design
- Phase 3 double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Jayne DRW, et al. N Engl J Med. 2021;384(7):599-609.doi 10.1056/NEJMoa2023386
Discussion & critique
Retracted in 2026. Nine primary-endpoint assessments were re-adjudicated after database lock and after unblinding, unknown to the two academic authors, who then asked the NEJM to withdraw the paper. The EMA found the trial in breach of good clinical practice and its data "incorrect and misleading", and the European Commission revoked the EU marketing authorisation in August 2026; the FDA had proposed withdrawal in April. Read as a record of what was claimed, not of what was shown.